Choice of antihypertensive agent in isolated systolic hypertension and isolated diastolic hypertension: A secondary analysis of the ALLHAT trial.

Autor: Wang SY; Department of Internal Medicine, Yale School of Medicine, New Haven, CT., Hanna JM; Department of Internal Medicine, Yale School of Medicine, New Haven, CT., Gongal P; Department of Internal Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH., Onuma OK; Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT., Nanna MG; Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT. Electronic address: michael.nanna@yale.edu.
Jazyk: angličtina
Zdroj: American heart journal [Am Heart J] 2022 Dec; Vol. 254, pp. 30-34. Date of Electronic Publication: 2022 Aug 04.
DOI: 10.1016/j.ahj.2022.07.006
Abstrakt: Despite broad treatment recommendations, there are limited published reports comparing the efficacy of different antihypertensive agents in patients with isolated systolic hypertension or isolated diastolic hypertension. This study was a secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. We compared the use of chlorthalidone, amlodipine, or lisinopril on the primary outcome of combined coronary heart disease, stroke, or all-cause mortality in patients with isolated systolic hypertension or isolated diastolic hypertension.
(Copyright © 2022 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: